statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of ELI-002-treated...

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023

Elicio Therapeutics GAAP EPS of -$6.96...

Elicio Therapeutics GAAP EPS of -$6.96

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR...

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing

BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing...

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, Elicio Therapeutics or Elicio ), a clinical-stage biotechnology company developing a pipeline of novel...

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear.
read more...

First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Volume	62,943.00
52-Wk High	$24.39
52-Wk Low	$2.96

ELTX Elicio Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals